London
· Delayed Price · Currency is GBP · Price in USD Blueprint Medicines Statistics
Total Valuation
Blueprint Medicines has a market cap or net worth of GBP 5.73 billion. The enterprise value is 5.61 billion.
| Market Cap | 5.73B |
| Enterprise Value | 5.61B |
Important Dates
The next estimated earnings date is Friday, February 14, 2025.
| Earnings Date | Feb 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.11% |
| Shares Change (QoQ) | +0.84% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 62.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 24.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -58.70 |
| EV / Sales | 15.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -30.00 |
Financial Position
The company has a current ratio of 3.32, with a Debt / Equity ratio of 2.34.
| Current Ratio | 3.32 |
| Quick Ratio | 3.10 |
| Debt / Equity | 2.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.92 |
| Interest Coverage | -5.49 |
Financial Efficiency
Return on equity (ROE) is -49.65% and return on invested capital (ROIC) is -17.05%.
| Return on Equity (ROE) | -49.65% |
| Return on Assets (ROA) | -14.97% |
| Return on Capital (ROIC) | -17.05% |
| Revenue Per Employee | 508,020 |
| Profits Per Employee | -149,745 |
| Employee Count | 655 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 0.89 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.59% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +38.59% |
| 50-Day Moving Average | 95.55 |
| 200-Day Moving Average | 97.10 |
| Relative Strength Index (RSI) | 72.76 |
| Average Volume (20 Days) | 352 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.04 |
Income Statement
In the last 12 months, Blueprint Medicines had revenue of GBP 324.12 million and -95.54 million in losses. Loss per share was -1.54.
| Revenue | 324.12M |
| Gross Profit | 314.47M |
| Operating Income | -205.89M |
| Pretax Income | -95.08M |
| Net Income | -95.54M |
| EBITDA | -195.57M |
| EBIT | -205.89M |
| Loss Per Share | -1.54 |
Balance Sheet
The company has 547.77 million in cash and 546.67 million in debt, giving a net cash position of 111.65 million.
| Cash & Cash Equivalents | 547.77M |
| Total Debt | 546.67M |
| Net Cash | 111.65M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 233.64M |
| Book Value Per Share | 3.68 |
| Working Capital | 445.56M |
Cash Flow
In the last 12 months, operating cash flow was -180.67 million and capital expenditures -6.25 million, giving a free cash flow of -186.91 million.
| Operating Cash Flow | -180.67M |
| Capital Expenditures | -6.25M |
| Free Cash Flow | -186.91M |
| FCF Per Share | n/a |
Margins
Gross margin is 97.02%, with operating and profit margins of -63.52% and -29.48%.
| Gross Margin | 97.02% |
| Operating Margin | -63.52% |
| Pretax Margin | -29.33% |
| Profit Margin | -29.48% |
| EBITDA Margin | -60.34% |
| EBIT Margin | -63.52% |
| FCF Margin | n/a |
Dividends & Yields
Blueprint Medicines does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.11% |
| Shareholder Yield | -3.11% |
| Earnings Yield | -1.67% |
| FCF Yield | -3.26% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Blueprint Medicines has an Altman Z-Score of 1.12. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.12 |
| Piotroski F-Score | n/a |